Prostate Brachytherapy

This phase 3 randomized investigation was designed to determine whether 30 months of androgen deprivation therapy (ADT) was superior to 6 months of ADT when combined with brachytherapy and external beam radiation therapy (EBRT) for localized high-risk prostate cancer. This study was conducted at 37 hospitals on men aged 40 to 79 years, with stage T2c-3a, prostate-specific antigen >20 ng/mL, or Gleason score >7, who received 6 months of ADT combined with iodine-125 brachytherapy followed by EBRT.

General Presentation A discussion of the changes in our financial condition and results of operations for the fiscal years ended June 30, 2022, 2021 and 2020, has been omitted from this report, but may be found in Item 7, MD&A, of our Annual Reports on Form 10-K for the years ended June 30, 2022 and June 30, 2021, filed with the SEC on September 28, 2022 and September 27, 2021, respectively, which are available free of charge on the SEC's website at www.sec.gov.